✓ Przywrócono płatność kartą kredytową — bezpieczne płatności przez Privacy Shield

Solu-Medrol

✅ Rapid inflammation relief
✅ Allergy symptom reduction
✅ Autoimmune disorder management
✅ Asthma attack alleviation
✅ Rheumatic condition treatment

Solu-Medrol contains Methylprednisolone.

Zweryfikowany medycznie przez Morgan Ellis — Badacz farmaceutyczny · 8 lat doświadczenia  · Ostatnia weryfikacja: maj 2026

Kup więcej, oszczędź więcej Cena za fiolkę
1 Vial/s
22,00 USD/fiolkę
US$22.00
2 Vial/s
US$20.00/vial · oszczędź 9%
US$40,00
3 Vial/s
US$18.00/vial · oszczędź 18%
US$54,00
6 Vial/s NAJLEPSZA WARTOŚĆ
US$17.00/vial · oszczędź 23%
US$102,00
Szyfrowana transakcja
Płać kryptowalutą – 10% taniej
Dyskretna dostawa na cały świat
1,400+ klientów · 50+ krajów

⚡ Quick Answer — What is Solu-Medrol?

Solu-Medrol is a sterile powder for reconstitution from Pfizer containing methylprednisolone sodium succinate 125 mg / 2 mL Act-O-Vial — a highly water-soluble pro-drug ester of methylprednisolone designed for rapid intravenous (IV) bolus or infusion when an immediate, large dose of glucocorticoid is needed. Onset of action is within minutes to 1 hour. Used for high-dose pulse therapy in MS relapse (1 g IV daily for 3–5 days), severe acute asthma, anaphylaxis after epinephrine, severe lupus or vasculitis flare, transplant rejection (induction and rescue), sight-threatening optic neuritis, and severe inflammatory ophthalmic disease. Lower doses (40–125 mg IV) are used as second-line in anaphylaxis, severe allergic reactions, and acute spinal cord injury (controversial). Pulse therapy carries a real risk of severe arrhythmia and sudden cardiac death — cardiac monitoring is standard during gram-doses. Other acute risks include severe psychiatric reaction, hyperglycaemia (especially in diabetes), and anaphylaxis to the drug itself. This is a hospital and supervised-clinic medication, not for patient self-administration.

⚕ Specialist-supervised medicine — clinician oversight required. This is a serious immunomodulatory drug with specific pre-treatment screening requirements, black-box warnings, and mandatory laboratory monitoring. It should be prescribed and supervised by a rheumatologist, gastroenterologist, dermatologist, or other specialist experienced with its use. Do otrzymuje, przechowuje, nie ma dostępu ani wglądu w dane osobowe przekazywane przez Ciebie dostawcy płatności. Proces weryfikacji odbywa się w całości na platformie dostawcy i podlega jego własnej polityce prywatności oraz standardom bezpieczeństwa. self-prescribe, self-adjust the dose, or start/stop without a prescriber's direction. Always provide your treating doctor with your current prescription before ordering from MedsBase.
Certyfikowane WHO-GMP manufacturer📦 Dyskretne opakowanie🌍 Wysyłka na cały świat💬 Ponad 1400 opinii klientów

📦 Każde zamówienie jest objęte naszą Reshipment Assurance Policy — jeśli Twoja przesyłka nie dotrze w ciągu 20 dni roboczych, wysyłamy ją ponownie.

Dlaczego warto zamawiać z MedsBase

Nasze leki generyczne pochodzą od producentów posiadających certyfikat WHO-GMP i są wysyłane na cały świat w dyskretnym, zwykłym opakowaniu — bez nazwy leku na zewnątrz przesyłki. Płatności kartami są kierowane przez regulowanego procesora (opis wyciągu zawiera nazwę regulowanego procesora płatności — nigdy “MedsBase” ani żadnej nazwy leku). Akceptujemy również kryptowaluty i przelewy bankowe SEPA. Każde zamówienie jest objęte naszą Reshipment Assurance Policy.

What Is Solu-Medrol?

Solu-Medrol is a sterile powder for reconstitution and intravenous bolus or infusion manufactured by Pfizer containing methylprednisolone sodium succinate — a synthetic corticosteroid in the glucocorticoid class. Glucocorticoids are the most powerful broad-spectrum anti-inflammatory and immunosuppressive drugs available, with effects across almost every tissue and organ system.

Solu-Medrol is Pfizer's original methylprednisolone sodium succinate — the standard hospital/emergency-room IV steroid. The 125 mg / 2 mL Act-O-Vial is the most-stocked strength worldwide and is used for severe acute asthma, anaphylaxis (after epinephrine), severe COPD exacerbation, MS relapse (in combination with additional vials for gram-doses), transplant rejection and severe autoimmune flares. Designed for in-hospital or supervised-clinic use, not patient self-administration.

Methylprednisolone 4 mg is approximately equivalent to prednisolone 5 mg (potency ratio ~5). The physiological daily cortisol output of a healthy adult is approximately 5–7.5 mg of prednisolone-equivalent — any dose above that is “supraphysiological” and begins to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Why methylprednisolone sodium succinate IV? Methylprednisolone itself is poorly water-soluble — impossible to inject IV at the gram-doses needed for pulse therapy. The sodium succinate ester is highly water-soluble, dissolves rapidly in the supplied diluent, and is hydrolysed in the blood to active methylprednisolone within minutes. The Act-O-Vial dual-chamber design keeps powder and diluent separate until reconstitution, extending shelf life and reducing pharmacist preparation time in the emergency setting where every minute counts.

How Does Solu-Medrol Work?

Methylprednisolone enters cells, binds the intracellular glucocorticoid receptor, and the receptor-drug complex translocates to the nucleus where it alters transcription of hundreds of genes. The end result is a broad dampening of the inflammatory cascade:

  • Suppresses pro-inflammatory cytokines (IL-1, IL-6, TNF-α, IFN-γ) and chemokines.
  • Stabilises lysosomal membranes, reducing release of proteolytic enzymes into tissue.
  • Inhibits phospholipase A2 via lipocortin, cutting off the prostaglandin and leukotriene pathways upstream.
  • Reduces capillary permeability and tissue oedema.
  • Suppresses B- and T-lymphocyte function and circulating lymphocyte counts (relative lymphopenia).
  • Reduces eosinophil and basophil activity, partially explaining the rapid effect in asthma, allergy and eosinophilic conditions.

Clinical onset (IV): genomic anti-inflammatory effects within 1–4 hours. At gram-doses, additional rapid non-genomic membrane-stabilising effects appear within minutes, contributing to the immediate symptomatic benefit seen in MS relapse, severe asthma and acute spinal cord injury.

— wzmacnia normalną odpowiedź fizjologiczną, a nie wywołuje ją sztucznie.

Solu-Medrol is used wherever an immediate, very large dose of glucocorticoid is needed and the patient cannot wait for oral absorption.

High-dose pulse therapy (gram-doses)

  • Multiple sclerosis relapse — 500–1,000 mg IV daily for 3–5 days, with or without oral taper
  • Acute optic neuritis — 1 g IV daily for 3 days
  • Acute renal transplant rejection — 250–1,000 mg IV daily for 3 days
  • Severe systemic lupus erythematosus or vasculitis flare — 500–1,000 mg IV daily for 3 days, followed by oral steroid + steroid-sparing agent
  • Sight-threatening Graves' ophthalmopathy — weekly 500 mg IV for 6 weeks, then 250 mg weekly
  • Severe interstitial lung disease flare

Lower-dose IV (40–500 mg)

  • Severe acute asthma not responding to nebulised bronchodilators — 40–125 mg IV every 6 hours
  • Anaphylaxis — second-line after epinephrine and antihistamines, 125 mg IV
  • Severe drug or contrast hypersensitivity reactions
  • COPD exacerbation in hospital — 40 mg IV every 6–12 hours when oral route is unsafe
  • Acute spinal cord injury — high-dose protocol (NASCIS), now controversial; many trauma centres no longer use it because of harm signal

Solu-Medrol is otrzymuje, przechowuje, nie ma dostępu ani wglądu w dane osobowe przekazywane przez Ciebie dostawcy płatności. Proces weryfikacji odbywa się w całości na platformie dostawcy i podlega jego własnej polityce prywatności oraz standardom bezpieczeństwa. appropriate for: maintenance therapy (switch to oral as soon as the patient can swallow), undiagnosed shock or sepsis without specialist review, or routine outpatient use.

Solu-Medrol Dosage and How to Use

Solu-Medrol is supplied as 125 mg / 2 mL Act-O-Vial. The Act-O-Vial dual-chamber system contains the lyophilised methylprednisolone sodium succinate powder in the upper chamber and the bacteriostatic water diluent in the lower chamber, separated by a stopper. Activate by pressing down on the plastic plunger to depress the stopper and release the diluent into the powder.

Typical adult IV doses

WskazanieMethylprednisolone doseUwagi
MS relapse500–1,000 mg IV daily × 3–5 daysNo oral taper required for short-duration pulse
Acute optic neuritis1 g IV daily × 3 daysFollowed by oral prednisolone 1 mg/kg × 11 days then taper (ONTT protocol)
Severe SLE / vasculitis flare500–1,000 mg IV daily × 3 daysFollowed by oral steroid + steroid-sparing agent
Acute renal transplant rejection250–1,000 mg IV daily × 3 daysFollowed by oral taper to maintenance
Severe acute asthma40–125 mg IV every 6 hoursSwitch to oral as soon as patient is stable enough to swallow
Anaphylaxis (adjunct, after epinephrine)125 mg IV bolusReduces biphasic reaction risk; not first-line
Severe COPD exacerbation in hospital40 mg IV every 6–12 hoursOral prednisolone is preferred when patient can swallow

How Solu-Medrol Is Administered

  1. Reconstitute the Act-O-Vial: hold the vial vertically, press the plastic plunger to release the diluent into the powder chamber, then gently agitate (do not shake violently) until the powder is fully dissolved — usually within 30 seconds. Solution is clear and colourless.
  2. Use within the labelled window after reconstitution — check the product insert; typically up to 48 hours when refrigerated.
  3. For doses up to 250 mg: slow IV bolus over at least 5 minutes. Faster bolus has been associated with severe arrhythmia and cardiac arrest.
  4. For doses 250 mg to 1 g: slow IV bolus over 30 minut or longer, OR infusion in 100–250 mL of saline or 5% dextrose over 30 minutes.
  5. For pulse therapy (1 g): infusion in 100–250 mL of saline over 30–60 minut. Cardiac monitoring is standard — bradyarrhythmia, atrial fibrillation, hypertensive crisis and (rarely) sudden cardiac death have all been reported.
  6. Keep oral steroid covered: when transitioning from IV to oral, do not stop the IV until the oral dose has been absorbed (overlap by at least one dose).
  7. Monitor capillary blood glucose 4-hourly during gram-dose infusions in any diabetic patient — expect significant hyperglycaemia requiring insulin.
  8. Monitor mood and orientation daily — pulse-dose steroid psychosis or severe insomnia is common, especially with night-time infusion timing. Schedule infusions for the morning when possible.
  9. Document: indication, dose, infusion duration, vital signs (BP, HR, glucose), reconstitution time, vial batch.

After Pulse Therapy — Taper, Cover and Monitoring

A 3–5 day pulse of 500–1,000 mg IV methylprednisolone alone usually does not require a taper — HPA suppression from such a short exposure recovers within 1–2 weeks. However, most pulse protocols are followed by an oral steroid course (e.g. prednisolone 1 mg/kg/day in optic neuritis, weeks of oral cover in transplant rejection or vasculitis). The oral course is what determines the eventual taper.

  • If oral steroid follows: taper depends on the duration and dose of the oral cover, not on the IV pulse.
  • If no oral steroid follows: monitor for fatigue, nausea, postural hypotension over the 1–2 weeks after the last pulse dose. A short morning hydrocortisone bridge may be needed if symptoms develop.
  • Surgical / illness cover: any patient who has had pulse-dose IV steroid within the past 6 weeks needs stress-dose hydrocortisone cover for major surgery, severe illness or sepsis — HPA suppression may persist longer than expected.
  • Cardiac, glucose, BP and mood monitoring for 24–72 hours after each gram-dose infusion. Many of the dramatic adverse events occur during or shortly after the infusion.

Side Effects of Solu-Medrol

Acute side effects of IV pulse-dose methylprednisolone are more dramatic and faster-onset than oral steroid equivalents, while long-term effects from short pulses are usually mild because of the limited duration of exposure.

Acute, during or shortly after infusion:

  • Bradyarrhythmia, atrial fibrillation, ventricular ectopy — particularly with rapid bolus or in patients with electrolyte abnormalities. Sudden cardiac death has been reported; cardiac monitoring is standard practice during gram-dose pulses.
  • Severe hypertensive surge in the first hour of infusion
  • Marked hyperglycaemia — expect blood glucose to rise sharply within hours; insulin scale almost always required in diabetes
  • Facial flushing, metallic or odd taste, perineal burning sensation — common with bolus, transient
  • Severe insomnia, agitation, mood swings, mania, frank psychosis — particularly with day 2–3 of pulse therapy
  • Acute hypokalaemia — may worsen arrhythmia risk; check potassium pre- and post-pulse

First few weeks after pulse:

  • Cushingoid appearance starting (less prominent than with oral courses)
  • Skin thinning, easy bruising
  • Insomnia, mood lability persisting
  • Increased infection risk (bacterial, viral, fungal, opportunistic)
  • Avascular necrosis of the femoral head — risk rises sharply with pulse therapy compared with oral steroid; warn the patient about new hip or knee pain.

Rare but serious — seek urgent review:

  • Sudden cardiac arrhythmia or arrest during or immediately after infusion
  • Severe psychiatric reaction (mania, psychosis) requiring inpatient psychiatric care
  • Disseminated severe infection (TB reactivation, opportunistic fungal, severe varicella, Pneumocystis)
  • GI bleed or perforation (especially with concomitant NSAIDs)
  • Anaphylaxis to the drug itself — rare but reported
  • Tumour lysis syndrome — in patients with bulky lymphoma or leukaemia receiving pulse steroid for the first time

Ostrzeżenia i środki ostrożności

  • Active or untreated infection — steroids mask signs of infection and worsen outcomes. Do not use for undiagnosed fever. Established infection sometimes still requires steroid (e.g. severe COVID-19) but specialist judgement only.
  • Latent TB — screen before any prolonged or repeated course; consider isoniazid cover if positive.
  • Cukrzyca — expect significant worsening; up-titrate oral hypoglycaemics or insulin during the course.
  • Hypertension, heart failure — methylprednisolone retains some sodium and fluid — BP and weight rise during pulse therapy.
  • Peptic ulcer disease, history of GI bleed, NSAID co-prescription — co-prescribe a PPI for any moderate-to-long course.
  • Osteoporosis risk — particularly relevant for patients receiving repeated IM depots or long oral courses.
  • Glaucoma and cataract — periorbital injection in particular can raise intraocular pressure; annual ophthalmology review for long-term users.
  • Psychiatric history — pulse-dose IV and high-dose oral steroid can trigger mania, depression, psychosis. Use the lowest effective dose; warn the patient and family.
  • Ciąża — methylprednisolone crosses the placenta; considered compatible with pregnancy when indicated for serious maternal disease, but routine elective use should be deferred.
  • Karmienie piersią — small amounts pass into milk; clinically insignificant at typical anti-inflammatory doses. After IV pulse, defer breastfeeding for 4 hours after a 1 g infusion to minimise infant exposure.
  • Dzieci — growth suppression is a real concern with prolonged use; monitor height and weight, use minimum effective dose for minimum duration.
  • Osoby w podeszłym wieku — higher risk of osteoporosis, diabetes, infection, psychiatric effects. Lower doses and shorter durations when possible.
  • Szczepionki żywe — contraindicated at immunosuppressive doses (after pulse therapy, defer live vaccines for at least 3 months). Inactivated vaccines (flu, pneumococcal, COVID-19, recombinant Shingrix) are fine.
  • Cardiac history — baseline ECG and serum potassium before gram-dose pulse. Continuous cardiac monitoring during the infusion of any dose > 250 mg, particularly in patients with heart failure, recent MI, or known arrhythmia.

Contraindications — Who Should NOT Receive Solu-Medrol

  • Known hypersensitivity to methylprednisolone, the vehicle (lactose, sodium succinate ester, sulphites in some formulations), or any related corticosteroid
  • Systemic fungal infection (unless specifically covered by antifungal therapy)
  • Untreated active bacterial, viral, mycobacterial or parasitic infection without appropriate treatment
  • Recent live vaccine administration at immunosuppressive doses
  • Cerebral malaria (corticosteroids worsen outcome)
  • Severe uncontrolled arrhythmia at the time of proposed pulse infusion (relative; balance against urgency)
  • Severe, unstable psychiatric disorder without psychiatric co-management (relative)

Interakcje lekowe

Łączyć zEfektCo robić
NLPZ (ibuprofen, diklofenak, naproksen)Major additive GI ulceration and bleed riskCo-prescribe a PPI; avoid long-term combination.
Warfarin, DOACsVariable INR change; increased GI bleed riskMonitor INR more frequently during dose changes.
Diabetes medicationsSteroids raise blood glucose significantlyExpect 1.5–3× higher insulin needs during course; up-titrate oral agents.
Antihypertensives, diureticsSteroids retain fluid, raise BPMonitor BP; up-titrate antihypertensives as needed.
Potassium-losing drugs (thiazides, loop diuretics, amphotericin)Additive hypokalaemia — increases arrhythmia risk during pulse infusionCheck potassium pre-treatment; supplement as needed.
Silne inhibitory CYP3A4 (ketokonazol, rytonawir, klarytromycyna)Raise methylprednisolone levels and prolong effectWatch for amplified steroid side effects; consider lower dose.
Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St John's wort)Lower methylprednisolone levels — loss of disease controlMay need 2–3× higher steroid dose; specialist review.
Live vaccines (MMR, varicella, yellow fever, BCG, live nasal flu, live Zostavax)Ryzyko rozsianego zakażenia szczepem szczepionkowymContraindicated at immunosuppressive doses, and for 3 months after stopping. Inactivated vaccines and recombinant Shingrix are safe.
DigoksynaHypokalaemia from steroids increases digoxin toxicity riskMonitor potassium and digoxin level.
Other immunosuppressants (methotrexate, azathioprine, cyclosporine, biologics, JAK inhibitors)Additive infection riskCombinations are common and often necessary — specialist supervision and infection-prophylaxis consideration.
QT-prolonging drugs, anti-arrhythmicsPulse steroid + electrolyte shifts may compound arrhythmia riskCardiac monitoring during infusion; check K+ and Mg2+ before and during.

Instrukcja przechowywania

  • Store the unreconstituted Act-O-Vial at 20–25°C, protected from light. Do not freeze.
  • After reconstitution: refrigerate (2–8°C) and use within the labelled stability window (typically 48 hours when stored properly — check the product insert).
  • Discard reconstituted solution that has been at room temperature for more than the in-use shelf life or that shows any cloudiness or particulates.
  • For IV infusion: dilute reconstituted solution in 5% dextrose or 0.9% sodium chloride; the diluted solution is stable for the labelled infusion period.
  • Przechowywać w miejscu niedostępnym dla dzieci.
  • Do not use after the expiry date on the pack.
  • Return unused product to a pharmacy for disposal — do not flush or discard in household waste.

Powiązane alternatywy w MedsBase

Other medications used in anti-inflammatory and autoimmune care stocked alongside this product:

Explore the full Leki przeciwzapalne i terapia autoimmunologiczna kategorię.

Najczęściej zadawane pytania

Why use IV Solu-Medrol instead of an oral steroid?

IV methylprednisolone delivers the entire dose into the circulation within minutes — oral absorption takes 30 minutes to 2 hours and absorbed dose can be reduced by GI illness, vomiting or shock. For conditions where every hour counts (MS relapse, anaphylaxis after epinephrine, severe asthma, transplant rejection, gram-doses for vasculitis or SLE flare), IV is the only practical route. Once the patient is stable, switch to oral as soon as possible — oral steroid at the same dose is bioequivalent and avoids the IV-specific risks of arrhythmia and rapid hyperglycaemia.

Is pulse-dose IV Solu-Medrol more dangerous than oral steroid?

Acute risks are higher: severe arrhythmia and (rarely) sudden cardiac death have been reported with rapid bolus or in patients with electrolyte abnormalities. Severe psychiatric reactions (mania, psychosis) are also more common with gram-doses than with oral therapy. However, total cumulative steroid exposure from a 3–5 day pulse is similar to a 2–3 week course of oral prednisolone — so the long-term risks of bone loss, cataract and persistent diabetes are usually lower than with extended oral therapy. The risk profile is “short and intense” vs “long and steady”.

Why does Solu-Medrol need cardiac monitoring during pulse therapy?

Rapid IV administration of large steroid doses causes acute electrolyte shifts (hypokalaemia, sometimes hypomagnesaemia), direct effects on cardiac conduction, and a sharp BP rise — together capable of triggering bradyarrhythmia, atrial fibrillation, ventricular ectopy and (rarely) cardiac arrest. Pre-pulse ECG, baseline potassium and magnesium check, and continuous cardiac monitoring during the infusion are all standard practice during gram-dose therapy.

What is the “flushing and metallic taste” sensation during infusion?

Common, transient, harmless sensations during IV bolus: facial flushing, a metallic or odd taste in the mouth, occasionally a perineal warming or burning sensation, and a brief sense of restlessness. These appear within minutes of the bolus and settle within an hour. Slowing the infusion rate reduces but does not always eliminate them. They are not allergic reactions and do not contraindicate further use.

How long does a 3-day pulse of Solu-Medrol suppress my own cortisol production?

HPA-axis suppression after a 3–5 day pulse of 500–1,000 mg/day usually recovers within 1–2 weeks. However, if the pulse is followed by a long oral taper (as is typical in optic neuritis, vasculitis, transplant rejection), HPA recovery is determined by the oral course duration, not the pulse. Stress-dose hydrocortisone cover is sensible for any major surgery, severe illness or sepsis within 6 weeks of a gram-dose pulse.

Will my blood sugar go up during pulse therapy?

Almost always — gram-dose IV methylprednisolone causes sharp hyperglycaemia within hours. Diabetic patients usually need a temporary insulin sliding scale during and for 24–48 hours after each pulse. Non-diabetic patients can develop transient steroid-induced hyperglycaemia that resolves within days. Check capillary blood glucose 4-hourly during the infusion period in any patient with known diabetes or risk factors.

Can I get an infection from a single IV pulse?

The acute infection risk from a 3–5 day pulse is real but lower than from a long oral course. The biggest concerns are: reactivation of latent TB or hepatitis B (screen before starting where possible), severe varicella or shingles in non-immune patients, and disseminated fungal infection in patients with prior risk factors. Pneumocystis prophylaxis is sometimes added for prolonged combination immunosuppression but is not standard for a short stand-alone pulse.

Why can't I just self-administer Solu-Medrol at home?

Pulse-dose IV steroid carries a real, immediate risk of arrhythmia, severe psychiatric reaction, anaphylaxis to the drug itself, and acute hyperglycaemia in diabetes. These need cardiac monitoring, IV access for emergency treatment, and trained staff to recognise and manage problems. Smaller doses (40–125 mg) are sometimes given by community nurses for severe asthma or anaphylaxis at home, but never the gram-doses used in MS or transplant rejection. Solu-Medrol is a hospital and supervised-clinic medication.

Is IV Solu-Medrol safe in pregnancy?

Methylprednisolone crosses the placenta to a limited extent (less than dexamethasone or betamethasone), so for maternal-indication therapy it is the preferred high-dose IV steroid in pregnancy — for example, treating an MS relapse or severe asthma exacerbation. Single short courses are well tolerated by the fetus; prolonged use is associated with intrauterine growth restriction. Always discuss with the obstetrician.

Dlaczego warto zamawiać z MedsBase

Solu-Medrol is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our Reshipment Assurance Policy. Przy płatności kartą w opisie transakcji widnieje nazwa regulowanego procesora płatności (regulowany procesor płatności kartowych), nigdy “MedsBase” ani nazwa leku.

Other Anti-Inflammatory & Autoimmune Medications

If Solu-Medrol does not suit your situation, the following options are available in this category:

More options in Anti Inflammatory & Autoimmune Care

Ranking według liczby ostatnich zamówień MedsBase — co wybierają inni klienci w tej kategorii.

Moc

125 mg / 2 ml

Ilość

1 Vial/s, 2 Vial/s, 3 Vial/s, 6 Vial/s

Opinie

Nie ma jeszcze opinii

Dodaj opinię
Solu-Medrol Solu-Medrol
Ocena*
0/5
* Ocena jest wymagana
* Odpowiedź jest wymagana
Twoja opinia
* Opinia jest wymagana
Imię
* Imię jest wymagane
Dodaj zdjęcia lub wideo do swojej opinii

Pytania i odpowiedzi

Zadaj pytanie
Solu-Medrol Solu-Medrol
Twoje pytanie
* Pytanie jest wymagane
Imię
* Imię jest wymagane
Nie ma jeszcze żadnych pytań